Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
placebo gel (Naval Aeromedical Research Unit, Dayton)
- Development stage
- Phase 3
- Lead developer
- Defender Pharmaceuticals
- Administration
- Intranasal
01
Overview
This placebo gel is an inactive control used in Phase 3 clinical trials conducted by the Naval Aeromedical Research Unit, Dayton (NAMRU-D) in collaboration with Defender Pharmaceuticals. It was specifically utilized in a randomized, double-blind study to evaluate the efficacy and safety of DPI-386 (an intranasal scopolamine gel) for the prevention and treatment of motion sickness among personnel on ocean-going vessels. The placebo gel is formulated to be physically indistinguishable from the active DPI-386 gel but contains no active pharmaceutical ingredient, serving to establish a baseline for comparing the therapeutic effects of scopolamine.
- Other names
- placebo nasal gel
Beyond the preview
Go deeper on placebo gel (Naval Aeromedical Research Unit, Dayton).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on placebo gel (Naval Aeromedical Research Unit, Dayton).